Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients.
Rituximab is being used as treatment for systemic autoimmune diseases. The objective of this study was to determine whether the genetic variant in the Fc gamma-receptor III a (FCGR3A) gene, 158F/V, contributes to the observed variation in response to rituximab in patients with systemic autoimmune diseases. DNA samples from 132 Spanish patients with different systemic autoimmune diseases receiving rituximab were genotyped for FCGR3A-158F/V (rs396991) gene polymorphism using the TaqMan(®) allelic discrimination technology. Six months after infusion with rituximab we evaluated the response to the drug: 61% of the patients showed a complete response, partial 27% and 12% did not respond to the treatment. A statistically significant difference was observed in V allele frequency between responder (38%) and nonresponder (16%) patients (p=0.01; odds ratio [OR]=3.24, 95% confidence interval [CI] 1.17-11.1). Rituximab was also more effective in V allele carriers (94%) than in homozygous FF patients (81%): p=0.02; OR=3.96, 95% CI 1.10-17.68. These results suggest that FCGR3A-158F/V (rs396991) gene polymorphism play a role in the response to rituximab in autoimmune diseases. Validation of these findings in independent cohorts is warranted.
Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN), CSIC, Granada, Spain.
Gema
G
Robledo
Ana
A
Márquez
Cristina Lucía
CL
Dávila-Fajardo
Norberto
N
Ortego-Centeno
José Luis Callejas
JL
Rubio
Enrique de Ramón
Ede R
Garrido
Julio
J
Sánchez-Román
Francisco J
FJ
García-Hernández
Raquel
R
Ríos-Fernández
Maria Francisca
MF
González-Escribano
Maria Teresa Camps
MT
García
Maria Jesús Castillo
MJ
Palma
Maria Del Mar
Mdel M
Ayala
Javier
J
Martín
D000483:Alleles; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000235:genetics*; D015331:Cohort Studies; D005260:Female; D005787:Gene Frequency; D006720:Homozygote; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020641:Polymorphism, Single Nucleotide; D017452:Receptors, IgG / Q000235:genetics* / Q000378:metabolism; D000069283:Rituximab; D044465:White People
D058846:Antibodies, Monoclonal, Murine-Derived; C496124:FCGR3A protein, human; D017452:Receptors, IgG; D000069283:Rituximab